Lundbeck has announced results from the parallel group, double-blind, randomized, placebo-controlled RELIEF study that assessed the efficacy and tolerability of Vyepti when initiated during a migraine attack in patients who are candidates for preventive therapy. The study met statistical significAlready a subscriber Login You have read all your free articles,…